The evolution of medulloblastoma therapy to personalized medicine
暂无分享,去创建一个
Scott Pomeroy | Soma Sengupta | Daniel Pomeranz Krummel | D. P. Pomeranz Krummel | S. Pomeroy | S. Sengupta
[1] David T. W. Jones,et al. Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing , 2014, Nature.
[2] D. Mitchell,et al. Know your neighbors: Different tumor microenvironments have implications in immunotherapeutic targeting strategies across MB subgroups , 2016, Oncoimmunology.
[3] Hans Clevers,et al. Wnt/β-Catenin Signaling and Disease , 2012, Cell.
[4] Words of wisdom. Re: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2014, European urology.
[5] Roland Eils,et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. , 2014, Cancer cell.
[6] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[7] Michael Kahn,et al. Can we safely target the WNT pathway? , 2014, Nature Reviews Drug Discovery.
[8] P. A. Futreal,et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.
[9] R. Moon,et al. WNT signalling pathways as therapeutic targets in cancer , 2012, Nature Reviews Cancer.
[10] Scott L. Pomeroy,et al. Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.
[11] Gary D. Bader,et al. Divergent clonal selection dominates medulloblastoma at recurrence , 2016, Nature.
[12] R. Packer,et al. Management of and prognosis with medulloblastoma: therapy at a crossroads. , 2008, Archives of neurology.
[13] R. Packer,et al. SHH inhibitors for the treatment of medulloblastoma , 2015, Expert review of neurotherapeutics.
[14] Could α5-GABA-A receptor activation be used as a target for managing medulloblastomas? , 2014, CNS oncology.
[15] M. Roussel,et al. Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. , 2016, Cancer cell.
[16] J. Olson,et al. DNA methylation of developmental genes in pediatric medulloblastomas identified by denaturation analysis of methylation differences , 2009, Proceedings of the National Academy of Sciences.
[17] Elaine R. Mardis,et al. Novel mutations target distinct subgroups of medulloblastoma , 2012, Nature.
[18] Michael C. Rusch,et al. Cancer-associated DDX3X mutations drive stress granule assembly and impair global translation , 2016, Scientific Reports.
[19] Arie Perry,et al. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy , 2016, Neuro-oncology.
[20] Scott L. Pomeroy,et al. Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.
[21] M. Kool,et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus , 2016, Acta Neuropathologica.
[22] B. Schoch,et al. Cerebellar mutism , 2004, Brain and Language.
[23] Roland Eils,et al. Active medulloblastoma enhancers reveal subgroup-specific cellular origins , 2016, Nature.
[24] R. McLendon,et al. Gorlin syndrome and desmoplastic medulloblastoma: Report of 3 cases with unfavorable clinical course and novel mutations , 2015, Pediatric blood & cancer.
[25] D. Ellison,et al. Molecular pathology of paediatric central nervous system tumours , 2017, The Journal of pathology.
[26] Scott L. Pomeroy,et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.
[27] Jessica M. Rusert,et al. Proteomic profiling of high risk medulloblastoma reveals functional biology , 2015, Oncotarget.
[28] Jill P. Mesirov,et al. MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.
[29] Matthew J. Betts,et al. Dissecting the genomic complexity underlying medulloblastoma , 2012, Nature.
[30] Scott L. Pomeroy,et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma , 2013, Acta Neuropathologica.
[31] Toshihiro Kumabe,et al. Cytogenetic prognostication within medulloblastoma subgroups. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] David T. W. Jones,et al. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] T. Zhou,et al. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. , 2013, Neuro-oncology.
[34] T. Merchant,et al. Children's Oncology Group's 2013 blueprint for research: Central nervous system tumors , 2013, Pediatric blood & cancer.
[35] J. Mesirov,et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Steven J. M. Jones,et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes , 2012, Nature.
[37] Michael C. Rusch,et al. Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[38] Yiai Tong,et al. Subtypes of medulloblastoma have distinct developmental origins , 2010, Nature.
[39] P. Bailey,et al. MEDULLOBLASTOMA CEREBELLI: A COMMON TYPE OF MIDCEREBELLAR GLIOMA OF CHILDHOOD , 1925 .
[40] J. Olson,et al. HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma. , 2016, Cancer cell.
[41] David T. W. Jones,et al. Transitioning from genotypes to epigenotypes: Why the time has come for medulloblastoma epigenomics , 2014, Neuroscience.
[42] David T. W. Jones,et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. , 2013, The Lancet. Oncology.